Sexual health

Suppressive Therapy: Daily Antivirals for Herpes

Save

Daily valacyclovir works as suppressive therapy, cutting herpes outbreaks for most people and roughly halving the risk of transmitting the virus to a partner. It does not remove risk entirely. Whether daily or episodic treatment fits depends on how often you have outbreaks and whether protecting a partner is a priority.

Last updated: July 2026

Talk to a clinician

A primary-care clinician

Gale can help you find one in your state and request a visit.

Find care →

What is suppressive therapy for herpes?

Suppressive therapy means taking a daily antiviral, such as valacyclovir, to keep the herpes virus quiet rather than treating each outbreak after it starts. The medicine lowers how often the virus reactivates, which reduces both visible outbreaks and the invisible asymptomatic shedding that can pass the virus to a partner.

Episodic therapy, by contrast, means a short course taken only when an outbreak begins. Suppressive therapy is usually a once-daily tablet taken continuously. According to the World Health Organization's self-care guideline, daily, self-managed care of this kind is a personal, ongoing choice rather than a requirement 1.

Does daily valacyclovir actually reduce outbreaks?

Daily valacyclovir reduces outbreaks for most people who take it consistently. Clinical trials have found that suppressive therapy cuts outbreak frequency substantially, often by around 70 to 80 percent, and many people go from several outbreaks a year to few or none.

The benefit tends to be largest for those who start with frequent recurrences, such as six or more a year, and breakthrough outbreaks are often milder and shorter. Because recurrent symptoms can weigh on mood and sexual confidence, fewer episodes often means better quality of life 2. Patient-facing resources also describe recurrent genital symptoms and when they warrant follow-up 3. The effect lasts only while the medicine is taken, so outbreaks can return if daily use stops.

Can daily antivirals lower the risk to a partner?

Daily antivirals lower the chance of transmitting herpes to a partner, though they do not remove it. A landmark transmission trial found that once-daily suppressive therapy reduced the risk of passing HSV-2 to a partner by roughly 48 percent compared with placebo.

Combining daily therapy with condoms and avoiding sex during outbreaks lowers risk further, because each measure blocks a different route. No single step is perfect, since the virus still sheds on about 10 percent of days. For couples where only one partner has herpes, layering these approaches is the practical goal rather than zero risk.

Episodic or daily: which approach fits?

Choosing between episodic and daily therapy comes down to how often you have outbreaks and what you want the medicine to do. A few considerations help weigh it: - Frequent recurrences, roughly six or more a year, often favor daily suppressive therapy. - Wanting to lower partner transmission risk favors a daily approach. - Occasional, predictable outbreaks may be treated episodically at the first sign of an outbreak. - Cost, convenience, and how you feel about a daily pill all matter.

Preferences also shift with life stage; outbreaks are often most frequent in the first year after a first infection and in younger adults, and many people find recurrences ease heading toward the perimenopausal years. Someone might use suppression early, then move to episodic treatment later. A clinician can help match the approach to your history 4.

When herpes suppression is worth discussing with a clinician

Deciding whether to start, continue, or step away from suppressive therapy is a conversation worth having with a clinician who knows your history. A primary care or sexual-health provider can weigh your outbreak frequency, your relationship situation, kidney health, and pregnancy plans, then match you to daily or episodic treatment and the right medication.

People planning a pregnancy especially benefit from reviewing antivirals ahead of time, which prepregnancy guidance recommends 5. If you are unsure where to start, learning how to become a new patient at a clinic makes the first visit easier, and Gale can help you organize your questions and outbreak history beforehand.

Common questions

For many people, suppressive therapy cuts outbreak frequency substantially, often by around 70 to 80 percent, and some people stop having outbreaks altogether while on it.

It lowers but does not eliminate the risk. A landmark trial found daily therapy roughly halved transmission to a partner, and combining it with condoms lowers risk further.

It depends on how often you have outbreaks and your goals. Frequent outbreaks or wanting to reduce partner risk favor daily therapy; occasional outbreaks may be managed episodically.

Daily antivirals are generally well tolerated over years for most people. A clinician can review your kidney health and reasons for use periodically, especially if you are pregnant or have other health conditions.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

A primary-care clinician

Gale can help you find one in your state and request a visit.

Find care →

When to revisit a herpes suppression plan

  • —Outbreaks that continue frequently despite daily antiviral therapy are a reason to seek clinician review of the plan.
  • —New or worsening symptoms while on suppressive therapy are a reason to seek clinical evaluation.
  • —Planning a pregnancy while on daily antivirals is a reason to seek clinician review before conception.
  • —Signs of an allergic reaction or unusual side effects are a reason to seek same-day medical care.

This article is general health education, not medical advice. Whether daily suppressive therapy fits you, and at what dose, is a decision for a primary care or sexual-health clinician who knows your history.

References

  1. 1.World Health Organization (2022). WHO guideline on self-care interventions for health and well-being, 2022 revision. World Health Organization (WHO). link ✓The WHO self-care guideline supports patient-initiated, self-managed sexual-health care, the general model for a daily suppressive antiviral taken at home.
  2. 2.American College of Obstetricians and Gynecologists (2019). Female Sexual Dysfunction: ACOG Practice Bulletin, Number 213. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003324 ✓ACOG's female sexual dysfunction bulletin documents how recurrent genital symptoms and related distress affect sexual well-being and quality of life.
  3. 3.MedlinePlus (National Library of Medicine) (2024). Vaginitis. MedlinePlus, U.S. National Library of Medicine (NIH). link ✓MedlinePlus describes recurrent genital symptoms and when they warrant clinical follow-up.
  4. 4.American College of Obstetricians and Gynecologists (2020). Vaginitis in Nonpregnant Patients: ACOG Practice Bulletin, Number 215. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003604 ✓ACOG's vaginitis bulletin supports the principle that recurrent genital symptoms are evaluated and managed in the outpatient setting.
  5. 5.American College of Obstetricians and Gynecologists (2019). ACOG Committee Opinion No. 762: Prepregnancy Counseling. Obstetrics & Gynecology. doi:10.1097/AOG.0000000000003013 ✓ACOG's prepregnancy counseling opinion recommends reviewing medications and infections before conception, relevant to planning antiviral use around pregnancy.

5 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — every citation independently verified. Editorial policy

← Back to the health library